Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2878 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Nov 2026, 03:15 UTC

2878

Studies in scope

industry-sponsored, all four open statuses

1386

Recruiting now

open to new participants

546

Lead sponsors

across recruiting studies

Top sites

London 2026 Manchester 676 Birmingham 483 Glasgow 436 Cambridge 425

Trials with a site in London

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Bradford, Cottingham, Glasgow, Harrow, London, Newcastle upon Tyne, Thetford, Wythenshawe

2025-06-27

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Bristol, Dundee, Exeter, London

2025-06-26

By invitation

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia

Avidity Biosciences, Inc.

Phase 3

199

London

2025-06-26

Recruiting

MowOot and Trans-anal Irrigation fOr coNstipation

NCT06833684Constipation Chronic Idiopathic

usMIMA S.L.

Not applicable

London

2025-06-25

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Glasgow, Leicester, London, Manchester, Sheffield, Southampton

2025-06-24

Recruiting

Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)

NCT06885931Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence

Amber Therapeutics Ltd

Not applicable

Bristol, London

2025-06-24

Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281Relapsing Multiple Sclerosis

DrugsRemibrutinib·Ocrelizumab

Novartis Pharmaceuticals

Phase 3

400

Sheffield, Leeds, London, Swansea

2025-06-23

Recruiting

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

NCT06464926Nausea, Vomiting

Enterra Medical, Inc.

Not applicable

148

London, Manchester

2025-06-23

By invitation

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

NCT07073014Hypochondroplasia

DrugVosoritide

BioMarin Pharmaceutical

Phase 3

140

London

2025-06-20

Recruiting

Bladder EpiCheck European Haematuria Study

NCT06818136Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter

Nucleix Ltd.

Observational

800

Dunfermline, Cambridge, Edinburgh, London, Surrey Quays

2025-06-20

Active, closed

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990Idiopathic Pulmonary Fibrosis

Calluna Pharma AS

Phase 2

150

Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton

2025-06-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Dundee, London, Norwich, Chichester, Belfast, High Wycombe, Sheffield

2025-06-19

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

210

Cornwell, London, Merthyr Tydfil, Salford, Surrey

2025-06-19

Recruiting

A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

NCT06786234Essential Thrombocythaemia

DrugSTP938

Step Pharma, SAS

Phase 2

Sheffield, Cardiff, London, Oxford, Southampton

2025-06-18

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport

2025-06-17

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall

2025-06-17

Recruiting

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

NCT06839235Primary Hyperoxaluria Type 1 (PH1)

Arbor Biotechnologies

Phase 1/2

Birmingham, London

2025-06-16

Recruiting

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation

DrugRLY-2608

Relay Therapeutics, Inc.

Phase 2

277

London

2025-06-13

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Bournemouth, Headington, Leeds, London, Metropolitan Borough of Wirral, Newcastle upon Tyne, Truro

2025-06-11

Recruiting

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1

DrugDel-brax

Avidity Biosciences, Inc.

Phase 3

200

London, Newcastle upon Tyne, Sheffield

2025-06-10

Active, closed

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

NCT06914609Angelman Syndrome

DrugObudanersen

Ionis Pharmaceuticals, Inc.

Phase 3

156

London, Oxford

2025-06-10

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London

2025-06-10

Recruiting

PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]

NCT06923111Sickle Cell Disease

Nova Laboratories Limited

Observational

180

Basildon, Cardiff, London, Manchester, Oxford

2025-06-09

Active, closed

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235Hidradenitis Suppurativa

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

149

Dudley, London

2025-06-09

Active, closed

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

NCT06953583Friedreich Ataxia

DrugsOmaveloxolone·Skyclarys

Biogen

Phase 3

255

London, Oxford, Sheffield

2025-06-09

Recruiting

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839Macular Edema

Boehringer Ingelheim

Phase 2

300

Camberley, Gloucester, Harrow, Liverpool, London, Newcastle upon Tyne, Sunderland, Westcliff-on-Sea

2025-06-05

Recruiting

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

NCT06797999Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma

Adcendo ApS

Phase 1/2

270

London

2025-06-05

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867Myelodysplastic Syndromes

DrugMomelotinib

GlaxoSmithKline

Phase 2

Boston, London, Manchester

2025-06-05

Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders

DrugSepofarsen

Laboratoires Thea

Phase 3

London

2025-06-04

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Cardiff, Glasgow, Leeds, Leicester, London

2025-06-04

Active, closed

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Glasgow, London, Sheffield

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth

2025-06-04

Recruiting

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

NCT06958536Crohn's Disease

DrugBrivekimig

Sanofi

Phase 2

Bury, Cambridge, Dagenham, London

2025-06-03

Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

DrugOctreotide LAR

Novartis Pharmaceuticals

Phase 3

240

Glasgow, London

2025-05-30

Recruiting

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06963021Major Depressive Disorder

DrugOsavampator

Neurocrine Biosciences

Phase 3

200

London, Salford, Sheffield, Southampton

2025-05-30

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

Chesterfield, Chippenham, Corby, Coventry, Harrow, Hull, London, Northwood

2025-05-28

Recruiting

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT06782373VEXAS, VEXAS Syndrome

DrugPacritinib

Swedish Orphan Biovitrum

Phase 2

156

Leeds, London, Oxford

2025-05-28

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Cambridge, Exeter, London

2025-05-28

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Birmingham, Glasgow, London

2025-05-27

Recruiting

EURO-STIM Registry

NCT06971796Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA)

Inspire Medical Systems, Inc.

Observational

1,000

London, Manchester

2025-05-26

Recruiting

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

NCT06941025Fabry Disease, Pregnancy, Pregnancy Complications

Chiesi Farmaceutici S.p.A.

Observational

London

2025-05-23

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester

2025-05-22

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Belfast, London, Southampton

2025-05-22

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Cottingham, Bristol, Cardiff, Coventry, Dundee, Glasgow, London, Manchester

2025-05-22

Active, closed

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830Hemophilia A

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

252

Birmingham, Cardiff, London, Manchester

2025-05-21

Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

4,200

Bristol, Clydebank, Exeter, Halifax, Harrow, London

2025-05-20

Active, closed

A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

NCT06962852Cystic Fibrosis

Boehringer Ingelheim

Phase 1/2

London

2025-05-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Cambridge, Manchester, London, Bradford, Crumpsall, Wakefield

2025-05-20

Recruiting

A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

NCT06581146X-Linked Myotubular Myopathy

Astellas Gene Therapies

Observational

Leeds, London, Oxford

2025-05-19

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Leeds, London, Woodville South

2025-05-19

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford

2025-05-19

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Dudley, Liverpool, London

2025-05-16

Recruiting

Crainio Non-invasive ICP Monitor for TBI

NCT06453733Traumatic Brain Injury

Crainio Ltda

Not applicable

London

2025-05-15

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

London, Stoke-on-Trent

2025-05-15

Recruiting

Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients

NCT06861361Symptomatic Severe Aortic Stenosis

Ceric Sàrl

Not applicable

1,180

Belfast, Brighton, Cambridge, Cottingham, Coventry, London, Newcastle upon Tyne, Sheffield

2025-05-15

Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

350

Salford, Dudley, London

2025-05-14

Active, closed

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852Head and Neck Squamous Cell Carcinoma

DrugsBI 770371·Cetuximab·Pembrolizumab

Boehringer Ingelheim

Phase 1

London, Sutton

2025-05-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Cambridge, London, Exeter, Birmingham, Northwood, Sutton, Devon

2025-05-13

Recruiting

Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk

NCT06670677Hypertension, Cardiovascular Risk, Blood Pressure Check (Hypertension Screening)

Aktiia SA

Observational

15,000

London

2025-05-12

Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

425

Bristol, Bury, Llanrhystud, London, Newcastle upon Tyne, Stockport

2025-05-12

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Cambridge, London, Glasgow

2025-05-12

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

587

London

2025-05-12

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

London, Preston, Leicester, Sheffield, Stoke-on-Trent

2025-05-08

Recruiting

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

NCT06662162Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration

i-Lumen Scientific AUS PTY LTD

Not applicable

100

Belfast, London, Middlesex, Sunderland

2025-05-07

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

DrugsCetuximab·Docetaxel

Revolution Medicines, Inc.

Phase 3

590

London, Liverpool, Nottingham, Sutton, Birmingham, Manchester

2025-05-06

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Cambridge, Leeds, London, Manchester

2025-05-06

Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548Advanced Lung Cancer

DrugsBNT324·Pumitamig

BioNTech SE

Phase 1/2

594

Bristol, Leeds, Liverpool, London, Manchester, Preston

2025-05-02

By invitation

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

NCT07055607Obesity

DrugsWegovy·Semaglutide

Novo Nordisk A/S

Observational

1,250

West Bromwich, Barnsley, Hull, London, Luton, Tooting

2025-05-01

Active, closed

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

NCT06924970Sickle Cell Disease

DrugTebapivat

Agios Pharmaceuticals, Inc.

Phase 2

London

2025-05-01

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD5492

AstraZeneca

Phase 1

Glasgow, London, Southampton

2025-05-01

Not yet open

Non-invasive Detection of Coronary Artery Stenosis

NCT06750016Coronary Arterial Disease (CAD)

Nilocas

Observational

London

2025-05

Active, closed

Pediatric Expansion Study of the Sentio System

NCT06976086Hearing Loss, Conductive, Hearing Loss, Mixed, Single Sided Deafness

Oticon Medical

Not applicable

Birmingham, London

2025-04-30

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

NCT06884618Neoplasms

Hoffmann-La Roche

Phase 1

405

Birmingham, London

2025-04-30

Active, closed

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)

DrugsPelacarsen·Inclisiran

Novartis Pharmaceuticals

Phase 3

246

Chichester, London, Manchester, Tyne and Wear

2025-04-30

Active, closed

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

AstraZeneca

Phase 1/2

Glasgow, London

2025-04-29

Active, closed

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240Von Willebrand Disease, Type 3

DrugsActivated Prothrombin Complex·Recombinant factor VIIa

Hoffmann-La Roche

Observational

London, Manchester

2025-04-29

Active, closed

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

NCT06836609Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis

DrugAln-Cideb

Regeneron Pharmaceuticals

Phase 1/2

118

London, Harrow

2025-04-28

By invitation

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

NCT06926621Myotonic Dystrophy Type 1 (DM1)

DrugVX-670

Vertex Pharmaceuticals Incorporated

Phase 2

Glasgow, London, Sheffield

2025-04-28

Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770Severe Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

288

Torquay, London, Dundee

2025-04-24

Recruiting

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463Metastatic Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin

AbbVie

Phase 2

390

London, Oxford, Sutton, Birmingham, Manchester

2025-04-24

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

London, Birmingham, Guildford

2025-04-24

Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer

DrugPumitamig

BioNTech SE

Phase 1/2

380

Cambridge, Cardiff, Leeds, London, Manchester, Sutton

2025-04-23

Active, closed

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

NCT06704269Generalized Myasthenia Gravis

Novartis Pharmaceuticals

Phase 1/2

Sheffield, London

2025-04-22

Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

NCT06953869Insomnia Disorder

DrugTasimelteon

Vanda Pharmaceuticals

Phase 3

420

Great Yarmouth, Leicester, Liverpool, London, Sheffield

2025-04-21

Active, closed

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

NCT06712563Pulmonary Disease, Chronic Obstructive

DrugBevacizumab

AstraZeneca

Observational

2,000

London

2025-04-17

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Exeter, Cottingham, London, Oxford, Stoke-on-Trent, Birmingham, Leeds, Cambridge

2025-04-17

Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401Major Depressive Disorder

DrugOsavampator

Neurocrine Biosciences

Phase 3

850

Southampton, Sheffield, London, Manchester

2025-04-16

Recruiting

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248Multiple Sclerosis

ModernaTX, Inc.

Phase 2

180

Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield

2025-04-16

Active, closed

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145Hypertension, Pulmonary

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

440

London

2025-04-16

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

Brighton, Fulham, Sutton, London, Manchester

2025-04-15

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Dudley, Harrow, Kings Lynn, London, Reading, Salford, Southampton, Wakefield

2025-04-15

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884Lymphoma, Large B-Cell, Diffuse

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2

594

Bristol, Aylesbury, Exeter, Plymouth, Middlesbrough, Lincoln, London, Oxford

2025-04-11

Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671CLL, Chronic Lymphocytic Leukemia

DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax

BeOne Medicines

Phase 3

250

Aberdeen, Birmingham, Bournemouth, London, Southampton

2025-04-10

Recruiting

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

NCT06846554Pulmonary Arterial Hypertension

Apollo Therapeutics Ltd

Phase 2

London, Bath, Cambridge, Clydebank, Sheffield

2025-04-09

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

Plymouth, Torquay, London

2025-04-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool

2025-04-09

Recruiting

A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

NCT06978725Cutaneous Sarcoidosis

DrugBrepocitinib

Priovant Therapeutics, Inc.

Phase 2/3

168

Coventry, London, Manchester

2025-04-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield

2025-04-09

Active, closed

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

NCT06459869Locally Advanced Rectal Cancer (LARC)

Akamis Bio

Phase 1

London, Sutton

2025-04-07

Recruiting

FORWARD CAD IDE Study

NCT06662500Coronary Arterial Disease (CAD)

Shockwave Medical, Inc.

Not applicable

408

Basildon, Bristol, Leeds, Leicester, London

2025-04-04

Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer

DrugsRibociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1/2

280

London

2025-04-03

Active, closed

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

NCT07108166COPD, Smoking, Tobacco Use

Philip Morris Products S.A.

Not applicable

290

Enfield, Glasgow, High Wycombe, London, Manchester, Metropolitan Borough of Wirral, Preston, Rochdale

2025-04-02

Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945Alopecia Areata

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 3

674

East Sussex, Dundee, London, Worthing

2025-04-01

Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450Advanced Solid Tumors Cancer, MSI-H Cancer

Nimbus Wadjet, Inc.

Phase 1/2

134

London, Manchester

2025-03-31

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton

2025-03-27

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay

2025-03-27

Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel

Daiichi Sankyo

Phase 3

510

Belfast, Dundee, London, Manchester, Plymouth, Sutton

2025-03-27

Active, closed

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

157

Plymouth, Hampstead, Bristol, Cambridge, Frimley, London

2025-03-20

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Leeds, Bristol, Cardiff, London, Southampton

2025-03-20

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

Cambridge, London, Manchester, Oxford, Sheffield

2025-03-19

Recruiting

Post-Market Data Collection to Evaluate the Performance of the Synergy Disc®

NCT06383962Cervical Degenerative Disc Disease

Synergy Spine Solutions

Observational

Birmingham, London

2025-03-17

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham

2025-03-17

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Paraplatin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds

2025-03-16

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance

2025-03-14

Active, closed

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048Neovascular Age-related Macular Degeneration (nAMD)

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Phase 4

274

Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton

2025-03-14

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290ANCA Associated Vasculitis (AAV)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

126

Cambridge, Glasgow, London, Manchester

2025-03-13

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Glasgow, Northwood, London, Manchester

2025-03-13

Active, closed

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

NCT06903338Viral Hepatitis

DrugsElebsiran·Tobevibart

Vir Biotechnology, Inc.

Phase 3

124

London, Manchester, Nottingham

2025-03-12

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield

2025-03-12

Active, closed

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Cambridge, London, Manchester, Metropolitan Borough of Wirral

2025-03-12

Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466Menstrual Migraine

DrugRimegepant

Pfizer

Phase 3

723

Bristol, Milton Keynes, Hull, London, Fazakerley, York, Glasgow, Sheffield

2025-03-11

Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

DrugIntismeran autogene

Merck Sharp & Dohme LLC

Phase 2

308

Glasgow, London, Torquay

2025-03-11

Active, closed

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

601

London, Coventry, Bradford, Harlow, Stoke-on-Trent, Wolverhampton

2025-03-10

Recruiting

Inari VISION Registry

NCT06600542Pulmonary Embolism

Inari Medical

Observational

1,000

Bristol, Glasgow, London, Manchester, Newcastle, Romford, Swindon

2025-03-07

Active, closed

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR

DrugALXN2030

Alexion Pharmaceuticals, Inc.

Phase 2

Birmingham, London

2025-03-07

Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 3

300

Birmingham, Bournemouth, Glasgow, Headington, London, Metropolitan Borough of Wirral, Plymouth

2025-03-05

Active, closed

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987APOL1-Mediated Kidney Disease

AstraZeneca

Phase 2

Birmingham, Leicester, Liverpool, London, Manchester

2025-03-05

Recruiting

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

NCT06842355Achondroplasia

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

London, Sheffield

2025-03-04

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

Glasgow, London

2025-03-04

Recruiting

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055Non-small Cell Lung Cancer

DrugsPumitamig·Docetaxel

BioNTech SE

Phase 2

Cardiff, Leeds, London, Manchester

2025-03-03

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London

2025-03-03

Active, closed

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

NCT06840483Breast Cancer

DrugZelenectide pevedotin

BicycleTx Limited

Phase 2

London

2025-03-03

Not yet open

Multivitamin Intervention and Cognitive Function

NCT06795789Healthy Adult, Cognitive Measures

Braincare Limited

Not applicable

London

2025-03-01

Recruiting

Vision Baby : The Measurement of Vital Signs in Neonates by Lifelight® Software in Comparison to the Standard of Care

NCT07799870Neonatal Diseases and Abnormalities, Vital Sign Monitoring

Xim Limited

Observational

256

London

2025-03-01

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Cambridge, Coventry, Dundee, London, Manchester, Sutton

2025-03-01

Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316Hepatocellular Carcinoma

Bayer

Phase 1

148

London, Glasgow, Sutton

2025-02-28

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Birmingham, Dudley, Ipswich, Liverpool, London, Poole, Redhill, Salford

2025-02-28

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

London, Liverpool, Manchester

2025-02-27

Active, closed

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126Uveal Melanoma, Ocular Melanoma

DrugRoginolisib

iOnctura

Phase 2

Northwood, Bebington, Glasgow, London, Southampton

2025-02-27

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester

2025-02-27

Recruiting

Tensi+ European Post-Market Clinical Follow-Up

NCT07205445Overactive Bladder

Stimuli Technology

Observational

500

Bristol, Cambridge, London

2025-02-27

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London

2025-02-27

Recruiting

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

NCT06686394Breast Neoplasms, Breast Cancer

DrugsOgivri·Herzuma·Patritumab deruxtecan·Tucatinib

Merck Sharp & Dohme LLC

Phase 1/2

181

London, Glasgow

2025-02-26

Recruiting

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 2

200

Birmingham, London

2025-02-25

Recruiting

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949Sjögren's Syndrome

DrugDazodalibep

Amgen

Phase 3

844

Portsmouth, Leeds, London

2025-02-25

Active, closed

Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants

NCT06738017Alpha 1-Antitrypsin Deficiency

BioMarin Pharmaceutical

Phase 1

Edinburgh, London, Southampton

2025-02-21

Active, closed

Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis

NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm

W.L.Gore & Associates

Observational

155

London

2025-02-20

Recruiting

Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment

NCT06598163Mild Cognitive Impairment

SharpTx

Not applicable

170

Exeter, Preston, Oxford, Taunton, London

2025-02-20

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Leeds, London, Manchester

2025-02-19

Recruiting

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

NCT06567782Neoplasms, Colon

DrugsCapeox·Dostarlimab

GlaxoSmithKline

Phase 2

120

Glasgow, Leeds West Yorkshire, London, Sutton

2025-02-18

Active, closed

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

NCT06727565Head and Neck Squamous Cell Carcinoma

DrugsDomvanalimab·Zimberelimab·Paclitaxel·Carboplatin

Gilead Sciences

Phase 2

London

2025-02-18

Recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268Sickle Cell Disease

DrugEtavopivat

Novo Nordisk A/S

Phase 3

510

Cambridge, London

2025-02-17

Recruiting

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505Chronic Migraine

DrugAtogepant

AbbVie

Phase 3

420

London, Gillingham, Aberdeen, Leeds, Stockport

2025-02-13

Recruiting

The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2

NCT06523400Myotonic Dystrophy

DrugMexiletine

Lupin Ltd.

Phase 3

176

London

2025-02-13

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Cardiff, Newcastle upon Tyne, Glasgow, London

2025-02-12

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

London, Oxford, Bradford, Newcastle upon Tyne

2025-02-12

Active, closed

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06806293Menstrual Migraine (MM)

DrugAtogepant

AbbVie

Phase 3

468

Poole, Brighton, London, Thetford, Oxford

2025-02-10

Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098Thrombocytopenia, Neonatal Alloimmune

DrugsImmunoglobulins·Nipocalimab·IVIG·Prednisone

Janssen Research & Development, LLC

Phase 3

Birmingham, Liverpool, London, Oxford

2025-02-10

Active, closed

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

NCT06780449Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

400

Bristol, Cambridge, Coventry, Liverpool, London, Swansea, Taunton

2025-02-10

Active, closed

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053Asthma

DrugGSK5784283

GlaxoSmithKline

Phase 2

307

Bradford, London, Newcastle upon Tyne

2025-02-10

Recruiting

Real World Evaluation of Lifelight®: A Contactless Vital Signs Monitor for Self-monitoring Blood Pressure and Its Comparison to Standard of Care

NCT06325384Hypertension

Xim Limited

Not applicable

500

London

2025-02-10

Active, closed

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920Generalized Myasthenia Gravis

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

180

London

2025-02-07

Recruiting

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3

Hemab ApS

Phase 1/2

108

Basingstoke, Tooting, Whitechapel, Birmingham, Cardiff, Leeds, Liverpool, London

2025-02-06

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Wigan, London, Taunton

2025-02-06

Active, closed

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239Systemic Sclerosis (SSc), Scleroderma

Zura Bio Inc

Phase 2

Aberdeen, Bath, Dundee, Leeds, Liverpool, London, Stoke-on-Trent

2025-02-06

By invitation

Use of TrachPhone in Tracheostomized Patients

NCT06487104Tracheostomy

Atos Medical AB

Not applicable

London

2025-02-05

Recruiting

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

NCT06830629Proteinuric Kidney Disease

Maze Therapeutics

Phase 2

Leicester, London

2025-02-05

Recruiting

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care

NCT06809686Heart Failure

Richmond Research Institute

Observational

1,000

London

2025-02-05

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

London, Glasgow, Birmingham, Newcastle upon Tyne

2025-02-04

Recruiting

A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine

NCT06772025Cardiac Surgery-associated Acute Kidney Injury

Bayer

Not applicable

100

Cambridge, Harefield, London

2025-02-03

Active, closed

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester

2025-02-03

Active, closed

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325Thyroid Eye Disease (TED)

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

320

Bristol, Cambridge, London, Newcastle

2025-02-03

Recruiting

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

NCT06487273Non-cystic Fibrosis Bronchiectasis

Physio-Assist

Not applicable

468

Belfast, Cambridge, Edinburgh, London, Newcastle upon Tyne

2025-02-03

Active, closed

WATER IV Prostate Cancer

NCT06651632Localized Prostate Cancer

PROCEPT BioRobotics

Not applicable

280

Basingstoke, Colney, London

2025-02-03

By invitation

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

170

Birmingham, Brighton, Bristol, Cambridge, Frimley, London, Oxford, Plymouth

2025-02-01

Recruiting

Study of Olutasidenib and Temozolomide in HGG

NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV

DrugOlutasidenib

Rigel Pharmaceuticals

Phase 2

London

2025-02-01

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Derriford, London, Oxford, Southampton

2025-01-30

Active, closed

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

NCT06809595Generalized Anxiety Disorder

DrugDT120

Definium Therapeutics US, Inc.

Phase 3

245

Glasgow, Gosforth, London, Manchester, Sheffield

2025-01-29

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester

2025-01-28

Active, closed

Clinical Study to Evaluate the Efficacy and Safety of Matrix Pro Treatment

NCT06726122Skin Laxity, Wrinkle, Skin Condition

Candela Corporation

Not applicable

Kings Hill, London

2025-01-28

Recruiting

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer

DrugFamotidine

Epkin

Phase 1

146

Glasgow, Leicester, London, Manchester, Oxford

2025-01-23

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Prednisolone·Methylprednisolone·Prednisone

Incyte Corporation

Phase 3

240

Bristol, Glasgow, Leeds, London, Manchester, Nottingham, Plymouth

2025-01-21

Recruiting

Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

NCT06639828Focal Liver Lesions

GE Healthcare

Phase 4

Bristol, London

2025-01-20

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)

Neuron23 Inc.

Phase 2

150

London, Newcastle upon Tyne, Dundee, Harrow

2025-01-17

Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126Melanoma, Cutaneous Malignant, Mucosal Melanoma

DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine

Immatics US, Inc.

Phase 3

450

Cambridge, Glasgow, London, Manchester, Oxford, Southampton

2025-01-14

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

NCT06754462Rheumatoid Arthritis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

120

Edinburgh, London, North Shields, Wolverhampton

2025-01-10

Recruiting

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226Sickle Cell Disease, Thalassemia

Novo Nordisk A/S

Phase 3

480

London, Manchester, Sheffield

2025-01-10

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib

Pfizer

Phase 3

1,035

Harlow, Truro, Maidstone, Taunton, Sutton, Coventry, Guildford, London

2025-01-06

By invitation

Evaluating Non-Invasive Haptics During Extreme Exercise

NCT07285252VO2max, Lactate Threshold, Lactate

SuperPatch Limited LLC

Not applicable

London

2025-01-05

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Birmingham, Glasgow, Harrow, Leeds, Lincoln, Liverpool, London, Swansea

2025-01-03

Recruiting

Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

NCT06769633Duchenne Muscular Dystrophy

Italfarmaco

Phase 2

Leeds, London, Newcastle upon Tyne, Oxford

2025-01-02

Recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910Crohn's Disease

DrugsVedolizumab·Upadacitinib

Takeda

Phase 3

396

London, Edinburgh, Glasgow

2025-01-02

Recruiting

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

NCT05098665Cardiac Amyloidosis

Richmond Research Institute

Not applicable

320

London

2025-01-01

Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

NCT06514612Acquired Blepharophimosis

Santen SAS

Phase 3

234

Leeds, London, Sunderland

2024-12-30

By invitation

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib

Janssen Research & Development, LLC

Phase 1

120

Leicester, London, Plymouth

2024-12-30

Active, closed

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

NCT06619509Solid Tumours

Boehringer Ingelheim

Phase 2

Cambridge, London

2024-12-30

Recruiting

Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)

NCT06805695Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn

iECURE, Inc.

Observational

London

2024-12-23

Active, closed

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Vertex Pharmaceuticals Incorporated

Observational

401

Birmingham, London, Newcastle upon Tyne, Sheffield

2024-12-19

Recruiting

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional

Chiesi Farmaceutici S.p.A.

Observational

170

London

2024-12-18

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield

2024-12-17

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Sheffield, London

2024-12-17

Recruiting

Ixovex-1 Single Agent and Combination Therapy

NCT06549946Solid Tumor, Head and Neck Cancer

DrugsKeytruda·Pembrolizumab

Psivac Ltd

Phase 1/2

London

2024-12-17

Recruiting

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406Metastatic Uveal Melanoma

DrugsRP2·Yervoy·Ipilimumab·Opdivo

Replimune, Inc.

Phase 2/3

280

Liverpool, London

2024-12-17

Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)

DrugUltomiris

Alexion Pharmaceuticals, Inc.

Observational

London

2024-12-16

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Greater London, Liverpool, London, Manchester, Sutton, Torquay

2024-12-16

Recruiting

The PERSEVERE Study

NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism

Inari Medical

Not applicable

200

London

2024-12-16

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Birmingham, Cottingham, London, Manchester

2024-12-13

Active, closed

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin

AbbVie

Phase 2

185

London, Oxford, Birmingham, Dundee

2024-12-13

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Birmingham, Hull, Leeds, London, Northwood

2024-12-12

Recruiting

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT06716606Connective Tissue Diseases

DrugBelimumab

GlaxoSmithKline

Phase 3

514

Leeds, London

2024-12-12

Recruiting

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT06669247Relapsed/Refractory Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

186

London, Manchester

2024-12-11

Active, closed

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

NCT06681324Crohn's Disease

DrugAZD7798

AstraZeneca

Phase 2

Birmingham, Cambridge, London

2024-12-11

Active, closed

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease

Laboratoires Thea

Phase 2

Headington, Edinburgh, London

2024-12-11

Active, closed

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

350

Leicester, Llanrhystud, London, Stockport

2024-12-11

Active, closed

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

NCT06784648Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent

DrugsIpilimumab·Keytruda·Pembrolizumab

BioInvent International AB

Phase 1/2

London

2024-12-11

Active, closed

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234Kidney Disease

DrugGSK4771261

GlaxoSmithKline

Phase 1

Cambridge, Exeter, London, Newcastle upon Tyne

2024-12-11

Recruiting

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

NCT06667453Myotonic Dystrophy 1

DrugPGN-EDODM1

PepGen Inc

Phase 2

Salford, London, Cardiff, Newcastle upon Tyne

2024-12-10

Recruiting

DERMATOMICS: Identifying Regulators of Skin Homeostasis

NCT06894654Systemic Sclerosis (SSc)

Relation Therapeutics

Observational

500

Leeds, London

2024-12-10

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Glasgow, London, Sutton

2024-12-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983Muscle-invasive Urothelial Carcinoma

DrugsAutogene cevumeran·Opdivo·Nivolumab

Hoffmann-La Roche

Phase 2

London

2024-12-09

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

London, Nottingham

2024-12-09

Active, closed

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma AB

Phase 2

378

Birmingham, Exeter, London, Manchester, Oxford

2024-12-09

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

West Midlands, London

2024-12-09

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908Carcinoma, Non-Small-Cell Lung

DrugsJNJ-90301900·Durvalumab

Johnson & Johnson Enterprise Innovation Inc.

Phase 2

130

London

2024-12-06

Active, closed

Phase 2b Open-Label Repeat Kidney Biopsy Study

NCT06740526IgA Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Leicester, London

2024-12-05

Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

NCT06603844Solid Tumor

Corbus Pharmaceuticals Inc.

Phase 1/2

156

Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London

2024-12-04

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon

2024-12-04

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Bellshill, Birmingham, Cardiff, Hexham, London, Manchester

2024-12-03

Active, closed

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 3

401

Newcastle upon Tyne, Salford, Oxford, Glasgow, Exeter, London

2024-12-03

Recruiting

Avapritinib Rollover Study

NCT06748001Mastocytosis, Systemic

DrugAvapritinib

Blueprint Medicines Corporation

Phase 4

London

2024-11-28

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

London, Manchester, Norwich, Nottingham, Plymouth

2024-11-27

Active, closed

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396Metastatic Breast Cancer

DrugsBelzutifan·Exemestane·Everolimus·Fulvestrant

Merck Sharp & Dohme LLC

Phase 2

120

Truro, London, Withington, Ipswich

2024-11-27

Active, closed

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

NCT06683742Wet Age Related Macular Degeneration, wAMD

DrugsEYP-1901·Aflibercept

EyePoint Pharmaceuticals, Inc.

Phase 3

400

London

2024-11-27

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne

2024-11-27

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester

2024-11-26

Recruiting

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281Crohn Disease, Colitis, Ulcerative

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,380

Prescot, London

2024-11-25

Active, closed

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

NCT06444113Multiple Sclerosis

Novartis Pharmaceuticals

Phase 4

Cambridge, London, Oxford, Salford

2024-11-25

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Glasgow, London, Manchester, Nottingham, Plymouth

2024-11-25

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich

2024-11-21

Active, closed

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

NCT06460506Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

Cardiff, Leeds, Liverpool, London, Southampton

2024-11-21

Active, closed

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

NCT06660667Neovascular Age-related Macular Degeneration

Sanofi

Phase 1/2

London, Liverpool

2024-11-21

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Birmingham, Harrow, London, Maidstone, Manchester, Oxford, Torquay

2024-11-19

By invitation

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06435312Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 3

Glasgow, London

2024-11-19

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne

2024-11-18

Recruiting

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

NCT06605378Chronic Granulomatous Disease (CGD)

Ensoma

Observational

London

2024-11-18

Active, closed

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease

DrugTaladegib

Endeavor Biomedicines, Inc.

Phase 2

213

Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry

2024-11-15

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Edinburgh, London, Manchester, Sutton

2024-11-14

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

London, Middlesbrough

2024-11-11

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London

2024-11-11

Active, closed

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155Systemic Sclerosis (SSc)

argenx

Phase 2

Leeds, London, Luton

2024-11-11

Active, closed

A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

NCT06713135Duchenne Muscular Dystrophy

DrugVamorolone

Santhera Pharmaceuticals

Phase 4

Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle

2024-11-10

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Ruislip, Corby, Nottingham, Oxford, Barnsley, Bradford, London

2024-11-07

Recruiting

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

NCT06663358Fabry Disease

DrugPegunigalsidase-alfa

Chiesi Farmaceutici S.p.A.

Observational

100

Edgbaston, Salford, London

2024-11-06

Recruiting

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT05582993Von Willebrand Disease (VWD)

DrugsAdvate·Vonicog Alfa

Takeda

Phase 3

London, Oxford

2024-11-06

Active, closed

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

NCT06647407Meningococcal Immunization, Healthy Volunteers

DrugsNimenrix·Vaxelis vaccine·Bexsero·Paracetamol

Sanofi Pasteur, a Sanofi Company

Phase 1/2

750

Exeter, London, Southampton

2024-11-05

Recruiting

First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

NCT06423690Lung Cancer

Snipe Medical

Not applicable

London

2024-11-01

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Liverpool, York, Bristol, London, Newcastle upon Tyne

2024-10-30

Recruiting

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia

Verve Therapeutics, Inc.

Phase 1

132

Liverpool, London, Manchester

2024-10-30

Active, closed

A Study of Mosliciguat in PH-ILD

NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases

DrugMosliciguat

Pulmovant, Inc.

Phase 2

135

Cambridge, London, Clydebank

2024-10-29

Recruiting

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension

Novartis Pharmaceuticals

Phase 1/2

232

Sheffield, Cambridge, London

2024-10-24

Active, closed

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

NCT06653153Alzheimer's Disease

DrugRemternetug

Eli Lilly and Company

Phase 3

1,400

Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth

2024-10-24

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

609

Blackburn, Westcliff-on-Sea, Edinburgh, Glasgow, London, Metropolitan Borough of Wirral, Swansea

2024-10-21

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth

2024-10-21

Recruiting

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860Diabetic Peripheral Neuropathic Pain

DrugPregabalin

Vertex Pharmaceuticals Incorporated

Phase 2

300

Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield

2024-10-18

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

Birmingham, Bradford, Coventry, Glasgow, Leicester, London, Truro

2024-10-18

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton

2024-10-18

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481Amyotrophic Lateral Sclerosis (ALS)

DrugVHB937

Novartis Pharmaceuticals

Phase 2

251

Sheffield, Farnborough, London, Stoke-on-Trent

2024-10-17

By invitation

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

NCT06559176Chronic Granulomatous Disease, Granulomatous Disease, Chronic

Prime Medicine, Inc.

Phase 1/2

London

2024-10-17

Recruiting

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 2/3

Glasgow, London

2024-10-16

Active, closed

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

NCT06637371Asthma

DrugAMG 691

Amgen

Phase 1

Cambridge, London, Manchester

2024-10-16

Active, closed

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462Eosinophilic Esophagitis (EoE)

DrugSolrikitug

Uniquity One (UNI)

Phase 2

184

Whitechapel, London

2024-10-16

Recruiting

Study of ATX-01 in Participants With DM1

NCT06300307Myotonic Dystrophy 1

ARTHEx Biotech S.L.

Phase 1/2

London

2024-10-15

Recruiting

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

NCT06585449Huntington's Disease

Alnylam Pharmaceuticals

Phase 1

Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory

Drugs) Berahyaluronidase alfa·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

Bodelwyddan, London, Oxford, Manchester

2024-10-14

Active, closed

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 3

London

2024-10-14

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham

2024-10-14

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Dundee, London, Manchester

2024-10-11

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Dudley, Ipswich, Liverpool, London, Poole, Redhill

2024-10-10

Active, closed

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

NCT06646289X-Linked Retinitis Pigmentosa

MeiraGTx Ocular UK Ltd

Phase 2

London

2024-10-10

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Exeter, Hull, Liverpool, London

2024-10-10

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

Leeds, London

2024-10-09

Active, closed

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

201

Bristol, London

2024-10-09

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286HIV-1-infection

DrugsISL/LEN·B/F/TAF

Gilead Sciences

Phase 3

609

Birmingham, Brighton, London

2024-10-09

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Brighton, Great Maze Pond, London

2024-10-08

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Exeter, Dundee, Larbert, Glasgow, London, Leicester, Manchester, Metropolitan Borough of Wirral

2024-10-07

Active, closed

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

NCT06513312Pre-Exposure Prophylaxis of HIV Infection

DrugsEmtricitabine/tenofovir disoproxil fumarate·Lenacapavir

Gilead Sciences

Phase 2

268

Birmingham, Brighton, Liverpool, London, Manchester

2024-10-07

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

London, Nottingham, Birmingham, Newcastle upon Tyne, Whitechapel

2024-10-04

Active, closed

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

768

Birmingham, Cambridge, Glasgow, Leicester, London, Manchester

2024-10-04

Recruiting

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805Primary Myelofibrosis

Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Phase 1

256

London, Oxford

2024-10-03

Recruiting

ALTO-100 in Bipolar Disorder With Depression (BD-D)

NCT06656416Bipolar Disorder I or II With a Major Depressive Episode

Alto Neuroscience

Phase 2

200

Derby, Edinburgh, Glasgow, Liverpool, London, Newcastle upon Tyne, Oxford, Southampton

2024-10-02

Active, closed

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

NCT06506955Advanced/Metastatic Cancer

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2/3

London

2024-10-01

By invitation

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency

Glycomine, Inc.

Phase 2

Birmingham, London

2024-09-30

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

Belfast, Liverpool, London, Southampton

2024-09-30

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Cambridge, Glasgow, Bradford, Chertsey, London

2024-09-30

Active, closed

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

NCT06421636Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Regeneron Pharmaceuticals

Phase 2

London

2024-09-30

Recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

NCT05663515Pancreatic Cancer

DrugExenatide

AstraZeneca

Observational

24,000

Edinburgh, London

2024-09-30

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne

2024-09-30

Active, closed

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,556

Truro, Brighton, London, Cheltenham, Northwood, Blackpool, Preston, Livingston

2024-09-27

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Bristol, Cambridge, Glasgow Strathclyde, Leeds West Yorkshire, Liverpool, London, Middlesbrough, Plymouth

2024-09-27

Recruiting

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss

GAP Innovations, PBC

Observational

1,200

Motherwell, London

2024-09-26

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London

2024-09-26

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Genmab

Phase 3

699

Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton

2024-09-25

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

108

Newcastle upon Tyne, Glasgow, London

2024-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

DrugSotagliflozin

Lexicon Pharmaceuticals

Phase 3

500

Glasgow, Leicester, Liverpool, London

2024-09-24

Active, closed

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis

ModernaTX, Inc.

Phase 3

37,864

High Wycombe, Runcorn, Truro, London, Orpington, Blackpool, Rochdale, Salford

2024-09-24

Active, closed

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446Refractory or Unexplained Chronic Cough

Nocion Therapeutics

Phase 2

455

Belfast, Bristol, Cottingham, London, Wythenshawe, Nottingham, North Shields

2024-09-24

Recruiting

Trial of THEO-260 in Ovarian Cancer Patients

NCT06618235Ovarian Cancer

DrugTHEO-260

Theolytics Limited

Phase 1/2

Glasgow, London, Oxford

2024-09-24

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay

2024-09-23

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Newcastle upon Tyne, Bury, London, Plymouth

2024-09-20

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Bristol, Headington, London, Newcastle upon Tyne

2024-09-19

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Brighton, Glasgow, Leeds, London, Southampton

2024-09-18

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Cambridge, Liverpool, London

2024-09-17

Active, closed

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999Multifocal Motor Neuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 2

London, Oxford, Salford

2024-09-17

Active, closed

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 4

500

Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton

2024-09-17

Active, closed

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

153

Bristol Avon, London

2024-09-17

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Leicester, Birmingham, London

2024-09-11

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

Birmingham, Belfast, Cambridge, Dundee, Edinburgh, Glasgow, Liverpool, London

2024-09-11

Active, closed

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis

Priovant Therapeutics, Inc.

Phase 3

371

London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Oxford, Glasgow, Birmingham, Cambridge, London

2024-09-11

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

High Wycombe, Ilford, Salford, London, Harrow

2024-09-04

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Sheffield, London

2024-09-04

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsTrosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff

2024-09-04

Recruiting

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer

Epsilogen Ltd

Phase 1

Bristol, Edinburgh, Leeds, London, Southampton

2024-09-03

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Cambridge, Clydebank, London, Newcastle, Sheffield

2024-09-03

Recruiting

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 1

142

Cambridge, Liverpool, London, Middlesex

2024-09-02

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

London, Sutton, Surrey

2024-08-31

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London

2024-08-30

Recruiting

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

NCT06610201Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3

Hemab ApS

Observational

200

London

2024-08-30

Active, closed

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391Melanoma

DrugsVancomycin·Keytruda·Pembrolizumab

Microbiotica Ltd

Phase 1

Brighton, Cambridge, Glasgow, London, Manchester, Newcastle, Sutton

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Birmingham, Cambridge, Leeds, Leicester, London, Northwood

2024-08-28

Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis

DrugsKYV-101·Fludarabine·Cyclophosphamide

Kyverna Therapeutics

Phase 2/3

Cambridge, London

2024-08-28

Active, closed

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers

DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel

BioNTech SE

Phase 2

Cottingham, Edinburgh, Leeds, London

2024-08-26

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

Belfast, Colchester, Eastbourne, Liverpool, London, Manchester, Newcastle upon Tyne

2024-08-26

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Leicester, London, Swansea

2024-08-26

Recruiting

Observational Study of Venus P-Valve

NCT05835349Right Ventricular Outflow Tract Dysfunction

Venus MedTech (HangZhou) Inc.

Observational

200

Leeds, London

2024-08-26

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Bristol, Cardiff, Leeds, London, Newcastle

2024-08-23

Active, closed

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer

Alterome Therapeutics, Inc.

Phase 1

110

London, Manchester, Newcastle upon Tyne, Sutton

2024-08-22

Recruiting

Abbott Structural Heart Device Registry

NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale

Abbott Medical Devices

Observational

2,500

London

2024-08-21

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

London, Inverness, Oxford

2024-08-21

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Plymouth, London, Southampton, Glasgow, Manchester, Newcastle upon Tyne

2024-08-19

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff

2024-08-16

Recruiting

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590Alzheimer Disease

Eli Lilly and Company

Phase 1

London, Sheffield, Southampton

2024-08-15

Active, closed

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Capecitabine

Novartis Pharmaceuticals

Phase 1/2

London, Sheffield

2024-08-14

Active, closed

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

NCT06496620COPD

DrugSolrikitug

Uniquity One (UNI)

Phase 2

182

Wythenshawe, Bradford, High Wycombe, London

2024-08-14

Active, closed

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

NCT05861999Muscular Atrophy, Spinal

DrugRisdiplam

Hoffmann-La Roche

Phase 4

London

2024-08-14

Recruiting

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer

DrugOlaparib

MOMA Therapeutics

Phase 1

220

London, Manchester, Newcastle upon Tyne

2024-08-13

Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies

DrugPelabresib

Novartis Pharmaceuticals

Phase 3

Cardiff, Glasgow, London

2024-08-13

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Birmingham, Dundee, Glasgow, Greater London, Leeds, London

2024-08-12

Active, closed

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

111

Cambridge, Sheffield, London, Norwich, Edinburgh

2024-08-08

Active, closed

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

London, Oxford

2024-08-08

Recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

220

London, Manchester

2024-08-07

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton

2024-08-07

Active, closed

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109Alopecia Areata

DrugRitlecitinib

Pfizer

Observational

450

Brighton, Dunfermline, Gloucester, Bath, Glasgow, London

2024-08-07

Active, closed

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06162572Non-small Cell Lung Cancer (NSCLC)

DrugsS095029·Cemiplimab

Servier Bio-Innovation LLC

Phase 1/2

102

London, Manchester

2024-08-07

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRemigromig·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

London, York, Bradford, Bristol, Liverpool, Sunderland, Wolverhampton

2024-08-07

Recruiting

Study of XB010 in Subjects With Solid Tumors

NCT06545331Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)

DrugPembrolizumab

Exelixis

Phase 1

396

Leicester, London, Manchester

2024-08-06

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide Decanoate·Enlicitide

Merck Sharp & Dohme LLC

Phase 3

3,000

London

2024-08-05

Active, closed

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer

DrugsPumitamig·Topotecan·Etoposide·Paclitaxel

BioNTech SE

Phase 2

110

Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne

2024-08-05

Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

NCT06297525Solid Tumor

DrugSTP938

Step Pharma, SAS

Phase 1

Glasgow, London, Manchester

2024-08-02

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro

2024-08-01

Recruiting

Vitaccess Real MG Registry

NCT06064461Myasthenia Gravis

Vitaccess Ltd

Observational

600

London, Birmingham

2024-07-31

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Inverness, Swinton, Birmingham, London, Southampton

2024-07-31

Active, closed

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

NCT06388083STGD1, Stargardt Disease 1

DrugTinlarebant

Belite Bio, Inc

Phase 2/3

London

2024-07-31

Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301Metastatic Non-small Cell Lung Cancer

DrugPembrolizumab

NovoCure GmbH

Phase 3

734

London, Leicester, Liverpool, Sutton

2024-07-31

Active, closed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

DrugVonaprument

Annexon, Inc.

Phase 3

659

Greater London, London

2024-07-30

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Swansea, Glasgow, Salford, Liverpool, Oxford, Cardiff, London, Newcastle upon Tyne

2024-07-30

Active, closed

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217Metastatic Neuroendocrine Prostate Cancer

Drugs[68Ga]Ga-PSMA-11·[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Ga-NeoB

Novartis Pharmaceuticals

Phase 1

Sutton, London

2024-07-29

Active, closed

A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

NCT06433557Achondroplasia

Ascendis Pharma Growth Disorders A/S

Phase 2

London

2024-07-26

Recruiting

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

NCT06520345Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3

520

London, Windsor

2024-07-26

Active, closed

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT06547216FSHD, FSHD1, FSHD2, FMD

DrugDel-brax

Avidity Biosciences, Inc.

Phase 2

London, Sheffield

2024-07-25

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

London, Sutton, Glasgow, Leeds, Manchester

2024-07-24

Recruiting

PulseSelect™ PFA Global Registry

NCT06393920Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

1,950

Coventry, London

2024-07-23

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

Cambridge, London, Newcastle, Southampton

2024-07-23

Active, closed

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616Alzheimer Disease

Janssen Pharmaceutica N.V., Belgium

Phase 2

Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth

2024-07-22

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752Relapsing Multiple Sclerosis, Multiple Sclerosis

TG Therapeutics, Inc.

Observational

2,000

London

2024-07-22

Recruiting

A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial

NCT06521047Acute Myocardial Infarction

CellProthera

Observational

Dundee, Edgbaston, Edinburgh, London

2024-07-20

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley

2024-07-19

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

London, Manchester, Surrey, Edinburgh

2024-07-19

Recruiting

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

NCT06405633Alpha-1 Antitrypsin Deficiency

Wave Life Sciences USA, Inc.

Phase 1/2

Birmingham, Cambridge, London

2024-07-19

Recruiting

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323Asthma

DrugDepemokimab

GlaxoSmithKline

Phase 3

150

Bradford, London, Southampton

2024-07-19

Recruiting

PMCF (Post-Market Clinical Follow-up) Study on The Tether™ in UK (United Kingdom)

NCT05830825Scoliosis Idiopathic

LDR Médical SAS

Observational

100

London, Newcastle upon Tyne, Southampton

2024-07-18

Active, closed

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

London

2024-07-17

Recruiting

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT06481306Anemia, Sickle Cell, Healthy Volunteers

DrugsFamotidine·Pantoprazole

Bristol-Myers Squibb

Phase 1/2

224

East Sussex, London, Leeds

2024-07-17

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsSotorasib·Panitumumab·Bevacizumab-awwb·Mvasi

Amgen

Phase 3

450

Birmingham, Glasgow, London, Maidstone, Northwood, Sheffield, Sutton

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Bodelwyddan, Gloucester, Lincoln, Boston, London, Newcastle upon Tyne, Newport

2024-07-16

Active, closed

HF-TRACK: A UK RCT of an Passive Heart Failure Monitoring and Tracking Device

NCT06334822Heart Failure

Heartfelt Technologies

Not applicable

186

Brough, Hull, Croydon, Bury St Edmunds, Horley, Keighley, Cambridge, London

2024-07-11

Recruiting

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

NCT06277037Long Term Follow-up

Arbutus Biopharma Corporation

Observational

Cardiff, London

2024-07-11

Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180Advanced Melanoma

DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab

Replimune, Inc.

Phase 3

400

Liverpool, London, Manchester

2024-07-11

Recruiting

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer

Context Therapeutics Inc.

Phase 1

156

London

2024-07-10

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

156

Edinburgh, London, Manchester, Oxford

2024-07-09

Active, closed

Versius Paediatrics Study

NCT06539442Robotic Surgical Procedures in Pediatric Urology

CMR Surgical Ltd

Not applicable

150

London, Manchester, Southampton

2024-07-08

Active, closed

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

NCT06248619Thyroid Eye Disease

DrugTeprotumumab

Amgen

Phase 3

London

2024-07-05

Recruiting

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

NCT06591793Usher Syndrome, Type 1B

AAVantgarde Bio Srl

Phase 1/2

London

2024-07-02

Recruiting

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594Solid Tumors, Neoplasms

DrugMocertatug rezetecan

GlaxoSmithKline

Phase 1

675

Cambridge, London

2024-07-02

Recruiting

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy

Walden Biosciences

Phase 2

Derby, Leicester, London, Manchester, Salford

2024-07-02

Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

DrugPembrolizumab

Eli Lilly and Company

Phase 1

460

London, Manchester

2024-07-01

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Cambridge, Leeds, London, Newcastle upon Tyne

2024-06-29

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

910

Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Truro, Dunfermline, Gloucester, London, Harrogate, Shoreham-by-Sea, Bristol, Newcastle upon Tyne

2024-06-27

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Genmab

Phase 3

621

Cambridge, Cardiff, Glasgow, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne

2024-06-25

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

London, Nottingham, Sheffield

2024-06-25

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

Birmingham, Glasgow, London

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Bristol, Hills Road, Truro, London, Edinburgh, Leeds

2024-06-24

Recruiting

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

NCT06188585Acute Gastrointestinal Bleeding

Medtronic - MITG

Not applicable

278

London

2024-06-21

Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder

CRISPR Therapeutics AG

Phase 1

Cambridge, London

2024-06-21

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

London, Coventry

2024-06-20

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Edinburgh, London, Wolverhampton

2024-06-20

Recruiting

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

NCT06389877Alpha 1-Antitrypsin Deficiency

Beam Therapeutics Inc.

Phase 1/2

192

Birmingham, London, Southampton

2024-06-19

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Barnet, Bristol, Exeter, Halifax, High Wycombe, London, Oldham, Sheffield

2024-06-17

Active, closed

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

NCT06455059Hypochondroplasia

DrugVosoritide

BioMarin Pharmaceutical

Phase 3

London

2024-06-17

Recruiting

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

NCT06504147Peritoneal Carcinomatosis, Ovarian Cancer

Oncoinvent Solutions AS

Phase 2

114

London, Southampton

2024-06-15

Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer

DrugTUB-040

Gilead Sciences

Phase 1/2

334

London

2024-06-12

Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

NCT06311682Atopic Dermatitis

DrugTralokinumab

LEO Pharma

Phase 3

195

Lincoln, London, Sheffield, Southampton

2024-06-10

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Londonderry, Torquay, London, Nottingham

2024-06-10

By invitation

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

NCT06112327Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia

Verve Therapeutics, Inc.

Observational

116

London

2024-06-09

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

London, Romford, Manchester, Sutton, Torquay

2024-06-07

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

London, Manchester, Norwich, Plymouth

2024-06-07

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Cardiff, London

2024-06-06

Recruiting

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976Hypochondroplasia

QED Therapeutics, a BridgeBio company

Observational

150

London, Manchester, Sheffield, Glasgow

2024-06-05

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol

2024-06-05

Recruiting

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

NCT06372717Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse

Apollo Therapeutics Ltd

Phase 1

100

Cardiff, Glasgow, London

2024-06-04

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield

2024-06-03

Active, closed

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

NCT05861986Muscular Atrophy, Spinal

DrugRisdiplam

Hoffmann-La Roche

Phase 4

London

2024-05-30

Active, closed

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731Age Related Macular Degeneration (ARMD)

DrugElamipretide

Stealth BioTherapeutics Inc.

Phase 3

313

Bristol, Leicester, London, Sunderland

2024-05-30

Active, closed

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 2/3

Liverpool, London

2024-05-29

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Birmingham, London

2024-05-29

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,800

Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth

2024-05-24

Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

NCT06402201Select Advanced Solid Tumors

CDR-Life AG

Phase 1

Sutton, Glasgow, London

2024-05-24

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis

DrugBomedemstat

Merck Sharp & Dohme LLC

Phase 3

400

London, Boston

2024-05-23

Active, closed

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 1

London, Sutton

2024-05-21

Active, closed

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

Cambridge, Glasgow, Preston, London, Birmingham

2024-05-20

Active, closed

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms

DrugsTucatinib·Disitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Sutton, London, Manchester

2024-05-20

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Exeter, Bournemouth, Bristol, Edinburgh, London, Sheffield, Swansea

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester

2024-05-19

Active, closed

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

NCT06393712Cerebral Amyloid Angiopathy

DrugsAln-App·Mivelsiran

Alnylam Pharmaceuticals

Phase 2

210

Glasgow, London

2024-05-17

Recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302Diabetic Retinopathy

Boehringer Ingelheim

Phase 2

175

Colchester, Liverpool, London, Newcastle upon Tyne

2024-05-15

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

NCT05419492Dravet Syndrome

DrugETX101

Encoded Therapeutics

Phase 1/2

113

Glasgow, London

2024-05-14

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne

2024-05-13

Active, closed

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

NCT06283212Dravet Syndrome

DrugETX101

Encoded Therapeutics

Phase 1/2

Glasgow, London, Sheffield

2024-05-09

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Portsmouth, Leicester, London, Glasgow

2024-05-08

Active, closed

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

NCT06294925Colitis, Ulcerative

DrugEtrasimod

Pfizer

Observational

360

Glasgow, Nottingham, Oxford, Edinburgh, Crumpsall, Kent, London, Newport

2024-05-08

Recruiting

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875AAA - Abdominal Aortic Aneurysm

W.L.Gore & Associates

Observational

2,000

Leicester, Liverpool, London

2024-05-07

Recruiting

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

NCT06138639Duchenne Muscular Dystrophy

Solid Biosciences Inc.

Phase 1/2

London

2024-05-06

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Cambridge, Dundee, London, Manchester

2024-05-03

Active, closed

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

NCT06402838Alzheimer's Disease

Hoffmann-La Roche

Phase 2

256

Chertsey, Edinburgh, London, Manchester, Southampton

2024-05-02

Recruiting

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease

DrugVERVE-102

Verve Therapeutics, Inc.

Phase 1

Birmingham, Cambridge, Edinburgh, London, Manchester, Nottingham

2024-04-30

By invitation

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

100

Birmingham, London, Salford

2024-04-30

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Preston, City of London, Exeter, London, Manchester

2024-04-29

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Salford, Dudley, London

2024-04-29

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Birmingham, Bradford, Coventry, Derby, Dorchester, Liverpool, London, Londonderry

2024-04-27

Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia

DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 2

London

2024-04-22

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Paraplatin·Taxol·Keytruda

Janssen Research & Development, LLC

Phase 1/2

287

Cambridge, Guildford, London, Manchester

2024-04-22

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton

2024-04-18

Active, closed

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221Cardiomyopathy, Hypertrophic

DrugMavacamten

Bristol-Myers Squibb

Phase 3

Belfast, London

2024-04-17

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol

2024-04-16

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Londonderry, Truro, London, Blackpool, Nottingham

2024-04-14

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Cheltenham, Inverness, London, Norwich, Preston, Truro

2024-04-11

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Cambridge, Glasgow, London, Edinburgh, Manchester

2024-04-10

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

London, Salford, Southampton, Stevenage

2024-04-09

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Leeds, London

2024-04-08

Active, closed

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

NCT06255782Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn

iECURE, Inc.

Phase 3

London, Newcastle upon Tyne

2024-04-08

Active, closed

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

NCT06029660Aortic Aneurysm, Abdominal

Shape Memory Medical, Inc.

Not applicable

180

London

2024-04-05

Active, closed

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132Generalized Epidermolysis Bullosa Simplex

TWi Biotechnology, Inc.

Phase 2/3

London

2024-04-04

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

398

Cottingham, Birmingham, Glenfield, London, Londonderry, Oxford, Exeter, Wolverhampton

2024-04-03

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Cambridge, Northwood, London, Oxford, Newcastle upon Tyne

2024-04-03

Recruiting

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

NCT06274515Breast Cancer

Hoffmann-La Roche

Phase 4

320

Basingstoke, London, Manchester

2024-04-02

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton

2024-04-01

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Cambridge, Doncaster, Leicester, London, Manchester, Reading, Stevenage

2024-03-29

Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

NCT06435000Stargardt, Stargardt's Disease, Stargardt Disease, STGD1

Splice Bio

Observational

London, Leeds, Manchester, Oxford

2024-03-29

Active, closed

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950Ulcerative Colitis

DrugZasocitinib

Takeda

Phase 2

213

London, Belfast, Cambridge

2024-03-29

Recruiting

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)

DrugsFT819·Fludara·Bendamustine·Cytoxan

Fate Therapeutics

Phase 1

244

Manchester, Cambridge, London

2024-03-28

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Torquay, London, Glasgow, Manchester

2024-03-28

Active, closed

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201Multiple Sclerosis, Myasthenia Gravis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

120

Manchester, London, Salford

2024-03-28

Active, closed

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934Ulcerative Colitis

Gilead Sciences

Phase 2

228

Bristol, Bury, Cambridge, Cardiff, London, North Shields

2024-03-27

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672Polycythemia Vera

DrugHydroxyurea

Italfarmaco

Phase 3

220

Belfast, Boston, London, Milton Keynes, Oxford, Southampton

2024-03-26

Recruiting

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia

DrugHS-10382

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2

330

London

2024-03-26

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808HIV-1-infection

DrugsBictegravir·B/F/TAF·Lenacapavir

Gilead Sciences

Phase 3

577

Liverpool, London

2024-03-25

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Cambridge, Glasgow, London, Oxford

2024-03-23

Recruiting

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

NCT06205121Pulmonary Sarcoidosis

Molecure S.A.

Phase 2

Birmingham, Cambridge, Edinburgh, London

2024-03-21

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

Edinburgh, Gloucester, London, Nottingham, Sutton, Wolverhampton

2024-03-21

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886Alzheimer Disease, Early Onset

DrugMoponetug

Bristol-Myers Squibb

Phase 2

310

Enfield, London, Bath, Chertsey

2024-03-20

Active, closed

Speech Performance and Clinic Efficiency With Remote Care Compared With Standard of Care in Adults With a Cochlear Implant in the First 12 Months Post-activation

NCT05552118Hearing Loss

Cochlear

Not applicable

148

Birmingham, Bodelwyddan, London

2024-03-18

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Glasgow, Cambridge, Edinburgh, Leicester, London, Manchester, Sutton

2024-03-18

By invitation

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder

Abbott Medical Devices

Not applicable

1,500

Brighton, London, Newcastle upon Tyne

2024-03-15

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Birmingham, Bristol, Liverpool, London, Manchester, Southampton

2024-03-14

Active, closed

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

NCT04850118X-Linked Retinitis Pigmentosa

DrugAGTC-501

Beacon Therapeutics

Phase 2/3

London, Oxford

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,350

High Wycombe, Bristol, Glasgow, Hull, London, Oxford, Portsmouth, Preston

2024-03-13

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel

2024-03-13

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Glasgow, London, Manchester, Oxford, Sheffield

2024-03-13

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Bristol, Guildford, Coventry, London

2024-03-12

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Reading, Portadown, Edinburgh, Leicester, Liverpool, London, Londonderry, Manchester

2024-03-07

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression

Bayer

Phase 1

198

London, Sutton, Newcastle upon Tyne

2024-03-07

Active, closed

Ryme Medical TLD Pilot Study

NCT05967091Chronic Obstructive Pulmonary Disease

Ryme Medical, Inc.

Not applicable

London

2024-03-06

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne

2024-03-05

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461Crohn's Disease

DrugZasocitinib

Takeda

Phase 2

268

Cambridge, London, Belfast

2024-03-05

Recruiting

A Study of Sepiapterin in Participants With Phenylketonuria (PKU)

NCT06302348Phenylketonuria

PTC Therapeutics

Phase 3

Birmingham, London

2024-03-04

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Cambridge, London, Manchester, Oxford, Taunton

2024-03-04

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=2

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,878 studies in total at the last sync on 07 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,026 of those studies with a site in London.

How many clinical trials are recruiting in London?

983 of the 2,026 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:15 UTC sync. A further 26 have not yet opened recruitment, 956 are active but closed to new participants, and 61 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.